RYSTIGGO®▼ infusion guide
Watch our video below to find out about the RYSTIGGO subcutaneous infusion process, from preparing for your patient through to following the infusion.
PI link: UK Rystigggo
Fintepla®▼ (fenfluramine) is indicated for the treatment of seizures associated with Dravet syndrome and Lennox-Gastaut syndrome as an add-on therapy to other antiepileptic medicines for patients 2 years of age and older.1
Rystiggo®▼ (rozanolixizumab) is indicated as an add-on to standard therapy for the treatment of generalised myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive.
Rystiggo currently not reimbursed on the NHS in Scotland.
Zilbrysq®▼ (zilucoplan) is indicated as an add-on to standard therapy for the treatment of generalised myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive.
GB-FA-2600055 | September 2026